High Blood Pressure & Cardiovascular Prevention

, Volume 19, Issue 4, pp 201–205 | Cite as

Omega-3 in Antiarrhythmic Therapy

Pros Position
  • Bruno Trimarco
Review Article


Omega-3 (n-3 polyunsaturated fatty acids) has demonstrated its ability to reduce global mortality, obtaining an indication for the prevention of sudden death in patients with myocardial infarction of the anterior wall. These observations have led to the design of several clinical studies aimed at demonstrating the potential antiarrhythmic effect of omega-3. These studies have given contradictory results, probably due to differences in the populations and doses used. Observations supporting the use of omega-3 as antiarrhythmic agents come from a study in patients with post-ischaemic dilatative cardiomyopathy and carriers of implantable cardioverter defibrillators (ICDs), without cardiovascular events in the last 12 months. In this population a combination of nutraceuticals containing omega-3 (Ritmonutra®) has been able to reduce the number of ventricular and supraventricular arrhythmias without modification of the left ventricle function. Specifically, a 46% reduction of premature ventricular contractions (BEV), 54.2% of premature supraventricular contractions (BESV), 48% of BESV run and 33% of sustained or non-ventricular tachycardia were observed (all significant, p < 0.0001).

In a following study, the antiarrhythmc effect of Ritmonutra® was evaluated by Holter ECG for 24 hours in patients with essential hypertension, without ischaemia, preserved left ventricular function and positive anamnesis for arrhythmia. The results showed that omega-3 treatment produced a significant reduction of ventricular and supraventricular arrhythmias compared with placebo, without modification of heart rate, intra-cardiac conduction and contractility.

A recent meta-analysis of studies conducted on omega-3 and possible reduction of cardiovascular events concluded that no significant beneficial effects are related to omega-3 treatment on reducing death for all cardiovascular events. Do these conclusions exclude omega-3 as an anti-arrhythmic?

We currently have no antiarrhythmic therapies showing a clear reduction of mortality, with the exception of amiodarone and β-blockers (β-adrenoceptor antagonists). This consideration is even more important for treatment of arrhythmias in healthy subjects, when the first goal is the relief of symptoms and improvement in quality of life. Keeping these last points in mind, the answer to the previous question is a loud ‘NO’, also taking into account the fact that omega-3, in contrast to the other antiarrhythmics, do not negatively affect myocardial contractility.


nutraceuticals cardiac arrhythmias quality of life 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kromhout D. n-3 fatty acids and coronary heart disease epidemiology: from Eskimos to Western populations. Nutr Bull 1990; 15(2): 93–102CrossRefGoogle Scholar
  2. 2.
    Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999 Aug 7; 354(9177): 447–55CrossRefGoogle Scholar
  3. 3.
    Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008 Oct 4; 372(9645): 1223–30PubMedCrossRefGoogle Scholar
  4. 4.
    Miller M, Cannon CP, Murphy SA, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008 Feb 19; 51(7): 724–30PubMedCrossRefGoogle Scholar
  5. 5.
    Lewis BS, Halon DA. More progression toward regression? Beyond low-density lipoprotein cholesterol lowering. J Am Coll Cardiol 2010 Jun 15; 55(24): 2743–4PubMedCrossRefGoogle Scholar
  6. 6.
    Studer M, Briel M, Leimenstoll B, et al. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med 2005 Apr 11; 165(7): 725–30PubMedCrossRefGoogle Scholar
  7. 7.
    Albert CM, Campos H, Stampfer MJ, et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med 2002 Apr 11; 346(15): 1113–8PubMedCrossRefGoogle Scholar
  8. 8.
    Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002 Apr 23; 105(16): 1897–903PubMedCrossRefGoogle Scholar
  9. 9.
    Kromhout D, Geleijnse JM, de Goede J, et al. n-3 fatty acids, ventricular arrhythmia-related events, and fatal myocardial infarction in postmyocardial infarction patients with diabetes. Diabetes Care 2011 Dec; 34(12): 2515–20PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Kromhout D, Yasuda S, Geleijnse JM, et al. Fish oil and omega-3 fatty acids in cardiovascular disease: do they really work? Eur Heart J 2012 Feb; 33(4): 436–43PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA 2006 Oct 18; 296(15): 1885–99PubMedCrossRefGoogle Scholar
  12. 12.
    Calo L, Bianconi L, Colivicchi F, et al. n-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol 2005 May 17; 45(10): 1723–8PubMedCrossRefGoogle Scholar
  13. 13.
    Nodari S, Triggiani M, Campia U, et al. n-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective, randomized study. Circulation 2011 Sep 6; 124(10): 1100–6PubMedCrossRefGoogle Scholar
  14. 14.
    Iovino GL, Vasta A, Liguori E, et al. Effects of nutraceuticals on ventricular and atrial arrhythmias in patients with CRT [abstract]. High Blood Press Cardiovasc Prev 2012; 19(2): 107–8Google Scholar
  15. 15.
    Izzo R, Trimarco V, Giudice R, et al. Effects of a combination of nutraceuticals on cardiac arrhythmias in hypertensive patients. Abstract presented at the SIPREC Conference; 2012 Mar 8–10; NaplesGoogle Scholar
  16. 16.
    Rizos EC, Ntzani EE, Bika E, et al. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012 Sep 12; 308(10): 1024-33PubMedCrossRefGoogle Scholar

Copyright information

© Adis Springer International Publishing AG 2012

Authors and Affiliations

  1. 1.Department of Internal Medicine and Cardiovascular SciencesFederico II UniversityNaplesItaly

Personalised recommendations